Zevering et al., 1999 - Google Patents
Naturally acquired human immune responses againstHelicobacter pylori and implications for vaccine developmentZevering et al., 1999
View PDF- Document ID
- 6743369911676702698
- Author
- Zevering Y
- Jacob L
- Meyer T
- Publication year
- Publication venue
- Gut
External Links
Snippet
Helicobacter pylori has been identified as a causative agent of gastroduodenal pathology. Vaccination studies with mouse models have shown that immunisation with bacterial antigens can provide protection against infection, indicating that it may be possible to design …
- 229960005486 vaccines 0 title abstract description 33
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0291—Yersinia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zevering et al. | Naturally acquired human immune responses againstHelicobacter pylori and implications for vaccine development | |
| D'Elios et al. | T helper 1 effector cells specific for Helicobacter pylori in the gastric antrum of patients with peptic ulcer disease | |
| Haeberle et al. | Differential stimulation of interleukin-12 (IL-12) and IL-10 by live and killed Helicobacter pylori in vitro and association of IL-12 production with gamma interferon-producing T cells in the human gastric mucosa | |
| AU695769B2 (en) | Helicobacter proteins and vaccines | |
| Yamamoto et al. | A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A | |
| Al-Mariri et al. | Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant | |
| Kao et al. | Helicobacter pylori-secreted factors inhibit dendritic cell IL-12 secretion: a mechanism of ineffective host defense | |
| Go et al. | Virulence and pathogenicity of Helicobacter pylori | |
| Kabir | The current status of Helicobacter pylori vaccines: a review | |
| Ferrero et al. | Local immunoglobulin G antibodies in the stomach may contribute to immunity against Helicobacter infection in mice | |
| Yunle et al. | Advances in Helicobacter pylori vaccine research: From candidate antigens to adjuvants—A review | |
| Paziak-Domańska et al. | Potential role of CagA in the inhibition of T cell reactivity in Helicobacter pylori infections | |
| Clapp et al. | Nasal vaccination stimulates CD8+ T cells for potent protection against mucosal Brucella melitensis challenge | |
| Dybing et al. | Role of endogenous interleukin-18 in resolving wild-type and attenuated Salmonella typhimurium infections | |
| Deml et al. | Characterization of the Helicobacter pylori cysteine-rich protein A as a T-helper cell type 1 polarizing agent | |
| Walduck et al. | Inflammation, Immunity, and Vaccines for H elicobacter pylori Infection | |
| Lillehoj et al. | Host immunity and vaccine development to coccidia and Salmonella infections in chickens | |
| Park et al. | Primary induction of CD4 T cell responses in nasal associated lymphoid tissue during group A streptococcal infection | |
| D’Elios et al. | Inflammation, immunity, and vaccines for Helicobacter pylori | |
| Espinosa-Ramos et al. | Immunization with a synthetic Helicobacter pylori peptide induces secretory IgA antibodies and protects mice against infection | |
| Yoshida et al. | Cloning and characterization of a novel membrane-associated antigenic protein of Helicobacter pylori | |
| Bosschem et al. | Species‐specific immunity to Helicobacter suis | |
| Liu et al. | Intranasal immunization with recombinant Toxoplasma gondii actin depolymerizing factor confers protective efficacy against toxoplasmosis in mice | |
| EP2262828B1 (en) | Compositions, methods and kits | |
| US20110033492A1 (en) | Vaccines for brucellosis |